Περίληψη:
Background: We sought to determine whether DNA damage response (DDR)-related aberrations predict therapeutic benefit in cisplatin-treated head and neck squamous cell carcinoma (HNSCC) patients and how DDR pathways are modulated after treatment with olaparib alone or in combination with cisplatin or durvalumab. Patients and methods: Oxidative stress, abasic sites and DDR-related parameters, including endogenous DNA damage, DNA repair mechanisms and apoptosis rates, were evaluated in HNSCC cell lines and peripheral blood mononuclear cells from 46 healthy controls (HC) and 70 HNSCC patients at baseline and following treatment with cisplatin-containing chemoradiation or nivolumab or enrolled in the OPHELIA phase II trial (NCT02882308; olaparib alone, olaparib plus cisplatin, olaparib plus durvalumab). Results: HNSCC patients at diagnosis exhibited deregulated DDR-related parameters and higher levels of oxidative stress and abasic sites compared with HC (all P < 0.05). Accordingly, nucleotide excision repair (NER; ERCC1, ERCC2/XPD, XPA, XPC) and base excision repair (APEX1, XRCC1) genes were downregulated in patients versus HC whereas double-strand breaks repair (MRE11A, RAD50, RAD51, XRCC2) and mismatch repair (MLH1, MSH2, MSH3) genes were overexpressed. Corresponding results were obtained in cell lines (all P < 0.001). Excellent correlations were observed between individual ex vivo and in vivo/therapeutic results, with cisplatin non-responders showing higher levels of endogenous DNA damage, augmented oxidative stress and abasic sites, increased NER capacities and reduced apoptosis than responders (all P < 0.05). Also, longer progression-free survival correlated with lower NER capacity (P = 0.037) and increased apoptosis (P = 0.029). Interestingly, treatment with olaparib-containing regimens results in the accumulation of cytotoxic DNA damage and exerts an extra antitumor effect by elevating oxidative stress (all P < 0.05). Nivolumab induced no significant changes in the DDR parameters examined. Conclusions: Aberrations in DDR signals are implicated in the response to HNSCC chemotherapy and can be exploited as novel therapeutic targets, sensitive/effective non-invasive biomarkers as well as for the design of novel clinical trials. © 2021 The Author(s)
Συγγραφείς:
Psyrri, A.
Gkotzamanidou, M.
Papaxoinis, G.
Krikoni, L.
Economopoulou, P.
Kotsantis, I.
Anastasiou, M.
Souliotis, V.L.
Λέξεις-κλειδιά:
DNA binding protein; DNA repair protein XRCC1; ERCC2 protein, human; xeroderma pigmentosum group D protein; XRCC1 protein, human; XRCC2 protein, human, DNA damage; DNA repair; genetics; head and neck tumor; human; mononuclear cell, DNA Damage; DNA Repair; DNA-Binding Proteins; Head and Neck Neoplasms; Humans; Leukocytes, Mononuclear; Squamous Cell Carcinoma of Head and Neck; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein
